Rozerem (Ramelteon) is the first in a novel class of sleep-promoting agents that targets the normal sleep-wake cycle—making it the first sleep agent with a new therapeutic mechanism of action in over 35 years. Rozerem is indicated for the treatment of insomnia charcterized by difficulty with sleep onset. And because it did not show evidence of abuse potential* or dependence in clinical studies, Rozerem is the first and only nonscheduled prescription insomnia medication.